Abstract
Background
Raloxifene acts like estrogen in preventing bone loss in postmenopausal women, but it selectively activates biological responses in bone tissue. It has a direct effect on osteoblasts’ differentiation and bone formation in bone marrow culture. However, the point at which raloxifene has an effect on bone marrow-derived mesenchymal stem cells (MSCs), regardless of sex difference, is not known. The purpose of this study was to examine the osteogenic effect of raloxifene on MSCs derived from female and male rats and to assess the sex difference of raloxifene with or without osteogenic supplements (OSs) in the regulation of bone formation.
Methods
Female and male rat bone marrow cells were cultured with or without OSs. In each experimental group, 10-6 M or 10-8 M raloxifene was added. As a control, cells were cultured without raloxifene. Histologically, mineralization was assessed by alizarin red S staining. Biochemically, alkaline phosphatase (ALP) activity, calcium content, and osteocalcin content were assessed.
Results
On histological analysis, mineralized nodules were seen on alizarin red S staining in the groups treated with OS. On the biochemical analysis, OS increased ALP activity, calcium content, and osteocalcin content. Among female groups with OSs, 10-6 M raloxifene significantly increased ALP activity, calcium content, and osteocalcin content compared with the controls. Among male groups, raloxifene had negligible effects.
Conclusions
10-6 M Raloxifene had no ossification-inducing effect on female MSCs, but it had an ossification-promoting effect; it had no osteogenic effect on male MSCs. Therefore, raloxifene has a sex difference with regard to its osteogenic effect on MSCs. Moreover, combined treatment with raloxifene plus OS has an effect on female MSCs. These results provide a useful insight into the possible influence of raloxifene after MSC transplantation in clinical practice.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Baker VL, Leitman D, Jaffe RB. Selective estrogen receptor modulators in reproductive medicine and biology. Obstet Gynecol Surv 2000;55:S21–S47.
Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial — Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282:637–645.
Goldstein SR, Johnson S, Watts NB, Ciaccia AV, Elmerick D, Muram D. Incidence of urinary incontinence in postmenopausal women treated with raloxifene or estrogen. Menopause 2005;12:160–164.
Neven P, Goldstein SR, Ciaccia AV, Zhou L, Silfen SL, Muram D. The effect of raloxifene on the incidence of ovarian cancer in postmenopausal women. Gynecol Oncol 2002;85:388–390.
Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 2000;95:95–103.
Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T. Expression of estrogen receptor beta in rat bone. Endocrinology 1997;138:4509–4512.
Qu Q, Perälä-Heape M, Kapanen A, Dahllund J, Salo J, Väänänen HK, et al. Estrogen enhances differentiation of osteoblasts in mouse bone marrow culture. Bone 1998;22:201–209.
Qu Q, Härkönen PL, Väänänen HK. Comparative effects of estrogen and antiestrogens on differentiation of osteoblasts in mouse bone marrow culture. J Cell Biochem 1999;73:500–507.
Maniatopoulos C, Sodek J, Melcher AH. Bone formation in vitro by stromal cells obtained from bone marrow of young adult rats. Cell Tissue Res 1988;254:317–330.
Zhou S, Turgeman G, Harris SE, Leitman DC, Komm BS, Bodine PV, Gazit D. Estrogens activate bone morphogenetic protein-2 gene transcription in mouse mesenchymal stem cells. Mol Endocrinol 2003;17:56–66.
Méndez-Dávila C, García-Moreno C, Turbì C, de la Piedra C. Effects of 17beta-estradiol, tamoxifen and raloxifene on the protein and mRNA expression of interleukin-6, transforming growth factor-beta1 and insulin-like growth factor-1 in primary human osteoblast cultures. J Endocrinol Invest 2004;27:904–912.
Van der Eerden BCJ, Emons J, Ahmed S, van Essen HW, Wit JM, Karperien M. Evidence for genomic and non-genomic actions of estrogens in growth plate regulation in female and male rats at the onset of sexual maturation. J Endocrinol 2002;175:277–288.
Van der Eerden BCJ, Gevers EF, Lowik CW, Karperien M, Wit JM. Expression of estrogen receptor alpha and beta in the epiphyseal plate of the rat. Bone 2002;30:478–485.
Sims NA, Clément-Lacroix P, Minet D, Fraslon-Vanhulle C, Gaillard-Kelly M, Resche-Rigon M, et al. A functional androgen receptor is not sufficient to allow estradiol to protect bone after gonadectomy in estradial receptor-deficient mice. J Clin Invest 2003;111:1319–1327.
Ohgushi H, Kotobuki N, Funaoka H, Machida H, Hirose M, Tanaka Y, et al. Biomaterials: tissue engineered ceramic artificial joint — ex vivo osteogenic differentiation of patient mesenchymal cells on total ankle joints for treatment of osteoarthritis. Biomaterials 2005;26:4654–4661.
Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, et al. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001;344:385–386.
Author information
Authors and Affiliations
About this article
Cite this article
Matsumori, H., Hattori, K., Ohgushi, H. et al. Raloxifene: its ossification-promoting effect on female mesenchymal stem cells. J Orthop Sci 14, 640–645 (2009). https://doi.org/10.1007/s00776-009-1357-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00776-009-1357-4